← Browse by Condition
Medical Condition

retinopathy of prematurity

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for retinopathy of prematurity sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — retinopathy of prematurity Clinical Trials

How many clinical trials are currently recruiting for retinopathy of prematurity?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for retinopathy of prematurity, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for retinopathy of prematurity?
retinopathy of prematurity research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a retinopathy of prematurity clinical trial?
Eligibility criteria for retinopathy of prematurity trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
Bayer 1 trial
Oregon Health and Science University 1 trial
Asociación para Evitar la Ceguera en México 1 trial

Recruiting Clinical Trials

NCT06315556
Recruiting
An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
Enrollment
200 pts
Location
United Kingdom
Sponsor
Bayer
View Trial →
NCT04420156
Recruiting
Clinical and Genetic Analysis of ROP
Enrollment
2,000 pts
Location
United States
Sponsor
Oregon Health and Science Univ...
View Trial →
NCT00346814 Phase 2, Phase 3
Recruiting
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome
Location
Mexico
Sponsor
Asociación para Evitar la Cegu...
View Trial →

Related Conditions

preterm infants (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology